Search results for "mother"

showing 10 items of 2331 documents

Human ectonucleotidase-expressing CD25 high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions

2015

IF 7.644; International audience; Th17 cells contribute to the development of some autoimmune and allergic diseases by driving tissue inflammation. However, the function of Th17 cells during cancer progression remains controversial. Here, we show that human memory CD25(high) Th17 cells suppress T cell immunity in breast cancer. Ectonucleotidase-expressing Th17 cells accumulated in breast cancer tumors and suppressed CD4(+) and CD8(+) T cell activation. These cells expressed both Ror gamma t and Foxp3 genes and secreted Th17 related cytokines. We further found that CD39 ectonucleotisase expression on tumor-infiltrating Th17 cells was driven by TGF-beta and IL-6. Finally, immunohistochemical …

0301 basic medicineAdenosineT cellImmunologyGeneration[SDV.CAN]Life Sciences [q-bio]/Cancerchemical and pharmacologic phenomenaBiology[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciencesInterleukin 21Immune systembreast cancerCancer stem cellmedicineCd73Immunology and AllergyChemotherapy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyIL-2 receptorRegulatory T-CellsSuppressionCarcinomaFOXP3hemic and immune systemsSuicide gene3. Good healthReceptor Ccr6030104 developmental biologymedicine.anatomical_structurePhenotypeOncologyImmunologyInterleukin 12[SDV.IMM]Life Sciences [q-bio]/ImmunologyTh17prognosisectonucleotidase
researchProduct

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced…

2019

Abstract Purpose: IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells (Treg). Navoximod is an investigational small-molecule inhibitor of IDO1. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of navoximod in combination with atezolizumab, a PD-L1 inhibitor, in patients with advanced cancer. Patients and Methods: The study consisted of a 3+3 dose-escalation stage (n = 66) and a tumor-specific expansion stage (n = 92). Navoximod was given orally every 12 hours continuously for 21 consecu…

0301 basic medicineAdultCancer ResearchIndoles[SDV]Life Sciences [q-bio][SDV.BC]Life Sciences [q-bio]/Cellular BiologyPharmacologyAntibodies Monoclonal HumanizedArticleB7-H1 Antigen03 medical and health sciences0302 clinical medicinePharmacokineticsAtezolizumabRenal cell carcinomaNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIndoleamine-Pyrrole 23-DioxygenaseNeoplasm MetastasisAgedNeoplasm StagingAged 80 and overBladder cancerbusiness.industryMelanomaImidazolesMiddle Agedmedicine.diseaseMagnetic Resonance Imaging3. Good health030104 developmental biologyTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisPharmacodynamicsPD-L1 inhibitorbusinessTomography X-Ray Computed
researchProduct

Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.

2020

Background: Triple-negative breast cancer (TNBC) is characterised by high pathological complete response to neoadjuvant chemotherapy (NAC). However, refractory and poor NAC responders still face very poor outcome, emphasising the urgent need for tools that facilitate identification of these patients, so that surgery or alternatives to NAC are considered early in the treatment protocol. Materials and methods: We combined metabolomics, exosome circulating miRNAs and flow cytometry experimental approaches in TNBC patients at diagnosis with immunohistochemistry in needle biopsy tumours to generate NAC-response predictive models. We also co-cultured and studied crosstalk between isolated patient…

0301 basic medicineAdultCancer Researchmedicine.medical_treatmentTriple Negative Breast NeoplasmsExosomesExosome03 medical and health sciences0302 clinical medicineImmune systemBreast cancerTriple-negative breast cancermicroRNABiomarkers TumorImmune ToleranceMedicineHumansIndoleamine-Pyrrole 23-DioxygenaseMetabolomicsProspective StudiesLiquid biopsyTriple-negative breast cancerCells CulturedAgedChemotherapybusiness.industryLiquid BiopsyTryptophanImmunosuppressionMiddle Agedmedicine.diseaseImmunohistochemistryCoculture TechniquesNeoadjuvant TherapyMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchFemaleNAC responsebusinessImmunosuppressionEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Serum Lycopene Concentrations and Associations with Clinical Outcomes in a Cohort of Maternal-Infant Dyads.

2018

Oxidative stress has been associated with adverse neonatal outcomes, and many carotenoids, including lycopene, potentially have antioxidant properties. The objective of this analysis was to explore the associations between serum lycopene concentrations, including lycopene isomers, and maternal-newborn outcomes. Maternal and cord blood samples were collected in 180 mother-infant pairs. Serum of total lycopene as well as the cis- and trans-isomers concentrations were measured using HPLC (High Performance Liquid Chromatography). Descriptive statistics were calculated; Spearman coefficients were used to assess correlations between maternal and cord concentrations. The relationship between lycop…

0301 basic medicineAdultCordBirth weightPhysiologyMotherslcsh:TX341-641AntioxidantsArticlelaw.inventionCohort Studies03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicinelawPregnancyIntensive Care Units Neonatalcarotenoid; lycopene; pregnancy; neonatal growthmedicineBirth WeightHumansPregnancyRespiratory Distress Syndrome Newborn030219 obstetrics & reproductive medicine030109 nutrition & dieteticsNutrition and DieteticsRespiratory distressbusiness.industryInfant NewbornInfantmedicine.diseaseFetal BloodlycopeneIntensive care unitCarotenoidsLycopenecarotenoid3. Good healthDietOxidative Stresschemistryneonatal growthCord bloodCohortFemalebusinesslcsh:Nutrition. Foods and food supplyFood ScienceNutrients
researchProduct

Antimicrobial photodynamic therapy using diode laser activated indocyanine green as an adjunct in the treatment of chronic periodontitis: A randomize…

2016

Abstract Introduction Clinical studies have shown the usefulness of antimicrobial photodynamic therapy (aPDT) as an adjunctive in periodontal therapy. These studies did not utilize indocyanine green (ICG) as a recently introduced photosensitizer. The aim of this study was to perform a full-mouth double-blind randomized controlled clinical study to test the efficacy of adjunctive aPDT with ICG compared with scaling and root planing (SRP) alone in chronic periodontitis treatment. Materials and methods Fifty patients were selected for this study. All patients received SRP. Then, each patient was randomly assigned to either the test group (aPDT + SRP) or the control group (SRP). aPDT was perfor…

0301 basic medicineAdultIndocyanine GreenMale030103 biophysicsGingival and periodontal pocketmedicine.medical_treatmentBleeding on probingBiophysicsDentistryPhotodynamic therapyDermatologylaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineScaling and root planingRandomized controlled triallawmedicineHumansPharmacology (medical)Photosensitizing Agentsbusiness.industryReproducibility of Results030206 dentistryMiddle AgedReference Standardsmedicine.diseaseChronic periodontitisOncologychemistryClinical attachment lossPhotochemotherapyChronic PeriodontitisFemalemedicine.symptomLasers SemiconductorbusinessIndocyanine greenPhotodiagnosis and photodynamic therapy
researchProduct

Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denm…

2016

BACKGROUND: The aim of the present EURECCA international comparison is to compare adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries.METHODS: Population-based national cohort data (2004-2009) from the Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), and Belgium (BE) were obtained, as well as single-centre data from Lithuania. All surgically treated patients with stage II colon cancer were included. The proportion of patients receiving adjuvant chemotherapy was calculated and compared between countries. Besides, relative survival was calculated and compared between countries.RESULTS: Overall, 59,154 patients …

0301 basic medicineAdultMaleCancer Researchmedicine.medical_specialtyAdjuvant chemotherapyColorectal cancerPopulationDiseasePopulation-basedStage II03 medical and health sciences0302 clinical medicinePharmacotherapySDG 3 - Good Health and Well-beingInternal medicineAntineoplastic Combined Chemotherapy ProtocolsJournal ArticlemedicineHumansStage (cooking)educationInternational comparisonAgedGynecologyeducation.field_of_studyRelative survivalbusiness.industryResearch Support Non-U.S. Gov'tMiddle Agedmedicine.diseaseSurvival AnalysisColon cancerAdjuvant chemotherapyEurope030104 developmental biologyLogistic ModelsOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsSurgeryFemalebusinessStage ii colon cancerEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Expression of salivary biomarkers in patients with oral mucositis: evaluation by SELDI-TOF/MS.

2016

Objective: This study aims to evaluate changes in proteomic salivary profile of patients with oral mucositis after adjuvant cancer treatments. Materials and Methods: Samples were collected from patients after adjuvant cancer therapies, and were analyzed by means of SELDI/TOF. Patients were separated in two groups: patients affected by mucositis (MUCOSITIS) and patient without mucositis (NO MUCOSITIS). All patients were divided in function of the anticancer treatment: patients who had radiotherapy (MUCOSITIS RADIO), had not radiotherapy (MUCOSITIS NO RADIO), had chemotherapy (MUCOSITIS CHEMO), and those who had not chemotherapy (MUCOSITIS NO CHEMO). Statistical evaluation PCA (Principal Comp…

0301 basic medicineAdultMalemedicine.medical_specialtySalivaPathologymedicine.medical_treatmentGastroenterologySELDI-TOF/MS; biomarker discovery; oral mucositis; saliva; Adult; Aged; Aged 80 and over; Biomarkers; Chemotherapy Adjuvant; Female; Humans; Male; Middle Aged; Neoplasms; Radiation Injuries; Radiotherapy Adjuvant; Saliva; Stomatitis; Spectrometry Mass Matrix-Assisted Laser Desorption-Ionization03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsbiomarker discoverymedicineMucositisHumansRadiation InjurieRadiation InjuriesSalivaGeneral DentistryStomatitisAgedAged 80 and overChemotherapyStomatitisbusiness.industryCancerSELDI-TOF/MSBiomarkerMiddle Agedmedicine.diseaseStomatitiRadiation therapy030104 developmental biologyOtorhinolaryngologyChemotherapy Adjuvant030220 oncology & carcinogenesisSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationBiomarker (medicine)NeoplasmFemaleRadiotherapy AdjuvantbusinessAdjuvantoral mucositiBiomarkersHumanOral diseases
researchProduct

Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7

2020

Monosomy 7 [-7] and/or partial loss of chromosome 7 [del(7q)] are associated with poor and intermediate prognosis, respectively, in myelodysplastic syndromes (MDS), but somatic mutations may also play a key complementary role. We analyzed the impact on the outcomes of deep targeted mutational screening in 280 MDS patients with -7/del(7q) as isolated cytogenetic abnormality (86 with del(7q) and 194 with -7). Patients with del(7q) or -7 had similar demographic and disease-related characteristics. Somatic mutations were detected in 79% (93/117) of patients (82% in -7 and 73% in del(7q) group). Median number of mutations per patient was 2 (range 0-8). There was no difference in mutation frequen…

0301 basic medicineAdultMalemyelodysplastic syndromes chromosome abnormalities prognosisCancer Researchmedicine.medical_specialtyAdolescentSomatic cellTp53 mutationGastroenterology03 medical and health sciences0302 clinical medicinePartial lossCytogenetic AbnormalityInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMutation frequencyAgedChromosome 7 (human)Aged 80 and overbusiness.industryMyelodysplastic syndromesHematologyMiddle Agedmedicine.diseasePrognosisSurvival AnalysisMutational analysis030104 developmental biologyOncology030220 oncology & carcinogenesisMyelodysplastic SyndromesMutationFemaleChromosome DeletionbusinessChromosomes Human Pair 7
researchProduct

Malignant PEComa With Metastatic Disease at Diagnosis and Resistance to Several Chemotherapy Regimens and Targeted Therapy (m-TOR Inhibitor).

2017

Perivascular epithelioid cell tumors (PEComas) are infrequent neoplasms with peculiar myomelanocytic differentiation. The aggressive abdominopelvic variant is rare, with only a small number of published cases. We present an additional case of this unusual variant, which showed an aggressive histologic and clinical behavior with multiple liver metastases and resistance to several therapies. We also discuss the histological and immunohistochemical profiles as well as the differential diagnosis.

0301 basic medicineAdultPathologymedicine.medical_specialtyPerivascular Epithelioid Cell Neoplasmsmedicine.medical_treatmentAntineoplastic AgentsDiseasePathology and Forensic MedicineTargeted therapy03 medical and health sciences0302 clinical medicineMedicineHumansMolecular Targeted TherapyChemotherapybusiness.industryTOR Serine-Threonine Kinasesmedicine.diseasePerivascular Epithelioid Cell Tumors030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisImmunohistochemistrySurgeryFemaleSarcomaAnatomyDifferential diagnosisbusinessInternational journal of surgical pathology
researchProduct

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric …

2021

Claudin 18.2 (CLDN18.2) is contained within normal gastric mucosa epithelial tight junctions; upon malignant transformation, CLDN18.2 epitopes become exposed. Zolbetuximab, a chimeric monoclonal antibody, mediates specific killing of CLDN18.2-positive cells through immune effector mechanisms.The FAST study enrolled advanced gastric/gastro-oesophageal junction and oesophageal adenocarcinoma patients (aged ≥18 years) with moderate-to-strong CLDN18.2 expression in ≥40% tumour cells. Patients received first-line epirubicin + oxaliplatin + capecitabine (EOX, arm 1, n = 84) every 3 weeks (Q3W), or zolbetuximab + EOX (loading dose, 800 mg/mIn the overall population, both PFS [hazard ratio (HR) = 0…

0301 basic medicineAdultmedicine.medical_specialtyAdolescentEsophageal NeoplasmsPopulationMedizinPhases of clinical researchAdenocarcinomaGastroenterologyLoading doseCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumanseducationCapecitabineeducation.field_of_studybusiness.industryHazard ratioAntibodies MonoclonalHematologyOxaliplatin030104 developmental biologyOncology030220 oncology & carcinogenesisClaudinsEsophagogastric Junctionbusinessmedicine.drugEpirubicinAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct